Specialty Biologic Drugs

FDA describes the US Purple Book as a database of FDA-licensed biological products, including CDER products and specified CBER categories. That is a biological-product registry scope, not a definition of every commercial specialty-drug offer. Identify the named product and distinguish a marketing category from its regulatory record.

No. FDA says some US biosimilars are approved as interchangeable and others are not; a company must specifically request that designation. An offer should state the particular product's status instead of extending interchangeability across the category. This distinction provides no treatment or substitution advice.

FDA says an interchangeable biosimilar may be substituted for its reference product without prescriber intervention, subject to state pharmacy law. A US advertiser should preserve that jurisdictional condition. The designation alone does not establish what a particular pharmacy will dispense or what an insurer will cover.

FDA identifies the US Purple Book as a searchable record of licensed biological products, biosimilars, interchangeable products and reference products, with product-label links. Suggested practice: verify the exact named product and label before publishing a status statement. This packet researches the verification route, not a particular medicine's record.

The reference benchmark is for Pharmaceutical Products.

Parent industry benchmark. Snapshot read 11 October 2026.

The exports section provides this edition in Markdown and JSON, along with a research index. Credit Madgicx Research & Labs and link to the exact source. Keep its snapshot date and scope.

Credit Madgicx Research & Labs and link to the exact source. Keep its snapshot date and scope.